in the synthesis and the processing of glycans (Jaeken and Matthijs 2007) . ALG8 deficiency (CDG Ih; OMIM 608104) is caused by pathological mutations in the ALG8 gene (Chantret et al. 2003) coding for the enzyme glucosyltransferase 2 (Dol-P-Glc:Glc1-Man 9 -GlcNAc 2 -P-P-Dol glucosyltransferase). This enzyme is responsible for the addition of the second glucose residue onto the growing lipid-linked oligosaccharide (LLO) chain (Chantret et al. 2003) . The ALG8 gene is located on chromosome 11 and spans 38.7 kbp. Translation of its 1404-nucleotide-long open reading frame, organized in 13 exons, results in a 467-amino-acid product.
So far, only five patients with ALG8 deficiency have been described (Chantret et al. 2003; Charlwood et al. 1997; Eklund et al. 2005; Schollen et al. 2004) , presenting with dysmorphic features, hypotonia, oedema, coagulopathy, gastrointestinal disorders including protein-losing enteropathy (PLE), hepatomegaly and cardiorespiratory problems. Four patients had neonatal onset and deceased in early childhood. One patient (Chantret et al. 2003 ) manifested later at the age of 4 month and survived beyond 3 years of age.
The aim of our study was to present a detailed clinical picture of a new ALG8-deficient patient with neonatal onset to further expand knowledge of the clinical symptoms in this disorder.
Case report
The girl was the first child of healthy, unrelated caucasian parents. The pregnancy after in vitro fertilization was complicated with oligohydramnios progressing to anhydramnios. The child was born at the 29th week of gestation with a birth weight of 1420 g and length of 38 cm by acute Caesarean section. Generalized oedema (anasarca) and mild hypotonia were observed from birth. Although, the early postnatal adaptation was viable, with Apgar score 8 and 9 at 5 and 10 min, respectively, multifocal myoclonic seizures and clinical signs of severe anaemia developed during the first day of life. She was ventilated and inotropic treatment was initiated. Each attempt at sucking from an endotracheal tube was complicated by mild bleeding episodes. Laboratory analyses at that time revealed pancytopenia (leukocytes 2.6Â10 9 /L, controls >5.5; haemoglobin 85 g/ L, controls >145; thrombocytopenia 61.10 9 /L, controls >150) and severe combined coagulopathy with very low levels of factor XI (2% in comparison with controls), antithrombin III (20%) and protein C (2%). Activated partial thromboplastin time (APTT) was markedly prolonged (>180 s). Almost no improvement of the coagulation status was seen after frequent administration of fresh frozen plasma, antithrombin III, protein C and factor VIIa concentrate. Haemorrhagic diathesis with bleeding necessitated repeated administration of packed red blood cells.
Although the clinical status appeared to be stabilized, from the third week of life progressive diarrhoea, intolerance of nasogastric tube feeding, abdominal distension and subsequent development of ascites and pericardial effusion were observed, as well as hypoalbuminaemia (21.6 g/L, controls >35 g/L). Bleeding predominated over tendency to thrombosis, but thrombosis of the vena cava inferior was documented at the age of 1 month. As a consequence of cardiac insufficiency and thrombotic episodes, liver congestion and portal hypertension developed, leading to marked hepatosplenomegaly.
Oedema was permanent with progressive course. Even though we did not study a 1 -antitrypsin clearance, the diagnosis of PLE was highly probable on the basis that maintenance of the normal concentration of albumin and immunoglobulins in blood necessitated practically continuous infusion of albumin (10% solution) and immunoglobulin substitution and that diarrhoea persisted and loss of albumin into the urine was minimal.
The seizures were under control on phenobarbital treatment, but generalized tonic seizures appeared at the age of 6 weeks. Brain ultrasound and eye investigations did not show any pathological findings until the age of 6 weeks, when mild cerebral cortical atrophy and bilateral optic nerve atrophy were observed.
The girl was oxygen-dependent on artificial lung ventilation or nasal continuous positive airway pressure until her death at the age of 2 months. The steatofibrosis with cholestasis found at the autopsy was striking, since no laboratory signs of liver failure or marked liver dysfunction were observed during the patient_s life. Brain postmortem studies revealed mild cerebellar atrophy, but showed no specific signs of cortical dysgenesis including the changes in the periventricular area typical for premature newborns.
The immediate cause of death was the progressive general oedema, bleeding and cardiorespiratory insufficiency leading to multiple organ failure.
Ethics
The study was carried out in accordance with the Declaration of Helsinki of the World Medical Associ-ation and was approved by the Committee of Medical Ethics of the Faculty of Medicine and General Teaching Hospital in Prague. Informed consent was obtained from the parents.
Methods

Biochemical methods
Isoelectric focusing (IEF) of serum transferrin was carried out as described by van Eijk and van Noort (1992) . Iron-saturated serum was incubated overnight at 37-C with neuraminidase from Clostridium perfringens (Boehringer-Ingelheim, Praha, Czech Republic), and subsequently separated by SDS-PAGE (5%T, 3%C; pH 3-10). PMM and PMI activities were measured in isolated lymphocytes according to the procedure described by Van Schaftingen and Jaeken (1995) .
LLOs and NLOs were prepared from control and patient fibroblasts as described previously (Haeuptle et al. 2008) . Briefly, the oligosaccharides were metabolically labelled by incorporation of [ 3 H]mannose. The LLOs were extracted with organic solvents and hydrolysed by mild acid treatment. NLOs were released from glycoproteins by incubation with PNGase F (New England BioLabs, Ipswich, MA, USA). Prior to HPLC analysis, the oligosaccharides were purified by ionic and hydrophobic chromatography.
Molecular methods
All 13 exons of the ALG8 gene amplified from patient_s gDNA were analysed on an ABI PRISM 3100-Avant Genetic Analyzer (Applied Biosystems, Foster City, CA, USA). The c.139A>C mutation was confirmed by restriction fragment length polymorphism using the MnlI restriction endonuclease. For confirmation of the c.1090C>T mutation, we designed mismatch primers for the HpaII enzyme.
Results
Biochemical analyses
The possible diagnosis of CDG in this patient was confirmed by detection of hypoglycosylated transferrin isoforms by IEF. The analysis revealed an abnormal glycosylation pattern, with decreased tetrasialo-and increased disialo-and asialo-transferrin, which is typical for CDG type I. Neuraminidase treatment excluded the possibility of a transferrin polymorphism. PMM2 and PMI activities measured in isolated lym- -GlcNAc 2 Man 9 Glc 1 in the patient_s cells. Enzymatically released NLO from control and patient fibroblasts yield qualitatively similar profiles (right panels). The retention times of Dol-PPGlcNAc 2 Man 1-9 (M 1-9 ) and -GlcNAc 2 Man 9 Glc 3 (G 3 ) are indicated at the top of panels phocytes and cultivated fibroblasts were normal, thus excluding CDG Ia and CDG Ib.
LLO analysis
In order to detect a possible defect in LLO assembly, skin fibroblasts isolated from the patient were labelled with 3 [H]mannose, and the glycans released from the lipid carrier were analysed by HPLC. The LLO profile of the patient showed the accumulation of incomplete precursor structures corresponding to GlcNAc 2 Man 9 and GlcNAc 2-Man 9 Glc 1 (Fig. 1, left panel) . This pattern is typical for ALG8 deficiency (CDG Ih) (Chantret et al. 2003) .
The accumulation of Dol-PP-GlcNAc 2 Man 9 observed in the patient may be due to the deglucosylation of Dol-PP-GlcNAc 2 Man 9 Glc 1 by ER glucosidase II, that has arisen owing to inefficient addition of the second glucose residue by the ALG8 glucosyltransferase. 
NLO analysis
The NLO analysis revealed an HPLC profile comparable to that obtained from healthy control subjects (Fig. 1, right panel) . This is in accordance with thinlayer chromatography analysis of NLO in an earlier ALG8-deficient patient (Chantret et al. 2003 ).
Molecular analyses
Two ALG8 mutations in heterozygous form were detected in the patient. The first mutation (c.139A>C), already described in the literature (Schollen et al. 2004) , was combined with a novel mutation c.1090C>T. The index mutation, which is translated into the missense mutation p.T47P, was inherited from the father. The c.1090C>T mutation resulting in a premature stop codon (p.R364X) was found in heterozygous form in the mother, whereas it was not found in 150 healthy controls.
Discussion
The clinical course of the disease in our patient demonstrates, similarly to the published cases (see Table 1 ), that the principal clinical and laboratory pathology is haemato-intestinal presentation. The majority of the patients were delivered prematurely and the first clinical symptoms, especially PLE, were presented during the first weeks of life. Only in one patient (surviving beyond 3 years of age) did PLE and diarrhoea develop later at the age of 4 months. Anaemia, pancytopenia, hypoalbuminaemia and coagulopathy were observed in most patients. Coagulopathy in patients with ALG8 deficiency appears to be caused by a combination of hypoproduction of both clotting factors and their inhibitors, and their increased consumption during chronic disseminated intravascular coagulation. The coagulopathy in our patient seems to be more accentuated with profound bleeding in contrast to patients with other CDG syndromes. Difficult-to-treat hypoalbuminaemia and coagulopathy resulted in the development of ascites, pericardial effusion, bleeding and early death.
Although craniofacial dysmorphy, inverted nipples and atypical fat pads were not present in our patient, dysmorphy was observed in three reported cases of ALG8 deficiency (Eklund et al. 2005; Schollen et al. 2004) , whereas inverted nipples and fat pads were noted in one case (Charlwood et al. 1997) . Since osteopenia, cataracts (Eklund et al. 2005) , lung hypoplasia (Schollen et al. 2004 ) and retinopathy (Chantret et al. 2003) were found only in a single child, we deduce that these symptoms cannot be considered typical for ALG8-deficient patients.
We did not observe elevated aminotransferases, but pronounced steatofibrosis with cholestasis was found at autopsy. Based on revision of clinical and laboratory reports from all six patients including our case, it seems that mild tubulopathy and proteinuria also belong to typical ALG8 deficiency symptoms. In addition, renal cortical and medullar microcysts were found in our patient.
Until the fifth case was published in 2005 by Eklund and colleagues (Eklund et al. 2005) , ALG8 deficiency had been presented as a type of CDG without neurological manifestations (Schollen et al. 2004 ). Eklund and colleagues described a patient who died at the age of 16 months and presented with psychomotor delay, hypotonia and leukoencephalopathy. In our case, we also observed marked hypotonia and multifocal myoclonic seizures from birth, bilateral optic nerve atrophy, cerebral cortical atrophy and mild cerebellar atrophy. On the other hand, the patient studied by Chantret and co-workers (Chantret et al. 2003) survived beyond 3 years (Eklund et al. 2005 ) and had no signs of any neurological impairment and, strikingly, PLE and diarrhoea subsequently disappeared. The mild clinical features of this patient could be explained by an elevated residual ALG8 expression. In summary, neurological impairment is not a general clinical symptom, but it has to be taken into consideration when thinking about ALG8 deficiency.
Conclusion
We present a new patient with ALG8 deficiency (CDG Ih), the sixth case described to date. The course of the disease in this new ALG8 case further expands the awareness of the diversity of clinical symptoms, which include multiorgan dysfunction with PLE, liver, kidney and central nervous system involvements and combined coagulopathy. Furthermore, we also identified a novel pathological mutation c.1090C>T (p.R364X) in the ALG8 gene. The diagnostics enabled genetic counselling and successful prenatal diagnostic in the affected family.
